Various water-soluble polysulphonated and polycarboxylated porphyrins and some of their metallated derivatives have been prepared and their antiviral properties against human immunodeficiency virus (HIV-1, HIV-2), simian immunodeficiency virus and other viruses are reported. Besides these polyanionic compounds, two new series of porphyrins were included and studied from the perspective of bio-availability modulation: (i) acefylsulphonamido derivatives endowed with weak acidity properties (deprotonation gives the corresponding anionic derivatives in a pH range 4.5-8.5) and (ii) compounds with the anionic charge transiently masked by esterification (acetoxymethyl- and pivaloyloxymethylesters). Among the more active compounds in inhibiting HIV-induced cytopathic effects, the sulphonated and carboxylated porphyrin complexes were found to interact directly with the HIV protein gp 120 and not with the CD4 cellular receptor.
AbramsDIKunoSWongRJeffordsKNashMMolaghanJBGorterR & VenoR (1989) Oral dextran sulfate in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Annals of Internal Medicine110: 183–188.
2.
AntipasA & GoutermanM (1983) Porphyrins. 44. Electronic states of Co, Ni, Rh and Pd complexes. Journal of the American Chemical Society105: 4896–4901.
3.
BabaMKonnoKShigetaS & De ClercqE (1987) In vitro activity of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against newly isolated clinical varicella-zoster virus strains. European Journal of Clinical Microbiology6: 158–160.
4.
Barrè-SinoussiFChermannJCReyFNugeyreMTChamaretSGruestJDauguetCAxler-BlinCVézinet-BrunFRouziouxCRozenbaumW & MontagnierL (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for AIDS. Science220: 868–871.
5.
BernadouJBonnafousMLabatGLoiseauP & MeunierB (1991) Biomimetic oxidation of acetaminophen and ellipticine derivatives with water-soluble metalloporphyrins associated to potassium monopersulfate. Drug Metabolism and Disposition19: 360–365.
6.
BonnettR (1995) Photosensitizers of the porphyrin and phthalocyanine series for photodynamic therapy. Chemical Society Reviews19–33.
7.
CampestriniS & MeunierB (1992) Olefin epoxidation and alkane hydroxylation catalyzed by robust sulfonated manganese and iron porphyrins supported on cationic ion-exchange resins. Inorganic Chemistry31: 1999–2006.
8.
CaponDJChamowSMMordentiJMarstersSAGregoryTMitsuyaHByrnRAWurmFMGroopmanJEBroderS & SmithDH (1989) Designing CD4 immunoadhesins for AIDS therapy. Nature337: 525–531.
9.
DaehneWVFrederiksenEGundersenELundFMorchPPetersenHJRoholtKTybringL & GodtfredsenWO (1970) Acyloxymethyl esters of ampicillin. Journal of Medicinal Chemistry13: 607–612.
10.
DanielMDLetvinNLSehgalPKHunsmannGScmidtDKKingNW & DesrosiersRC (1987) Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. Journal of General Virology68: 3183–3189.
11.
DebnathAKJiangSStrickNLinKHaberfieldP & NeurathAR (1994) Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1. Journal of Medical Chemistry37: 1099–1108.
12.
De ClercqEDescampsJVerhelstGWalkerRTJonesASTorrencePF & ShugarD (1980) Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. Journal of Infectious Diseases141: 563–574.
13.
De ClercqEHolyARosenbergISakumaTBalzariniJ & MaudgalPC (1986) A novel selective broad-spectrum anti-DNA virus agent. Nature323: 464–467.
14.
De ClercqESakumaTBabaMPauwelsRBalzariniJRosenbergI & HolyA (1987) Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Antiviral Research8: 261–272.
15.
De ClercqE (1991) Basic approaches to anti-retroviral treatment. Journal of Acquired Immune Deficiency Syndromes4: 207–218.
16.
De ClercqE (1994) HIV resistance to reverse transcriptase inhibitors. Biochemical Pharmacology47155–169.
17.
De ClercqE (1995a) Antiviral therapy for human immunodeficiency virus infections. Clinical Microbiology Reviews8: 200–239.
18.
De ClercqE (1995b) Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. Journal of Medicinal Chemistry38: 2491–2517.
19.
DingLBalzariniJScholsDMeunierB & De ClercqE (1992) Anti-human immunodeficiency virus effects of cationic metalloporphyrin-ellipticine complexes. Biochemical Pharmacology44: 1675–1679.
20.
DixonDWKimMSKumarVObaraGMarzilliLG & SchinaziRF (1992) Amino- and hydroxytetraphenylporphyrins with activity against the human immunodeficiency virus. Antiviral Chemistry and Chemotherapy3: 279–282.
21.
FauldsD & BrogdenRN (1992) Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs44: 94–116.
22.
FielRJMusserDAMarkEHMazurchukR & AllettoJJ (1990) A comparative study of manganese meso-sulfonatophenylporphyrins: contrast-enhancing agents for tumors. Magnetic Resonance Imaging8: 255–259.
23.
FisherRABertonisJMMeierWJohnsonVACostopoulosDSLiuTTizardRWalkerBDHirschMSSchooleyRT & FalvellRA (1988) HIV infection is blocked by recombinant soluble CD4. Nature331: 76–78.
24.
GaggeroNRobertABernadouJ & MeunierB (1994) Oxidation of SR 48117, an antagonist of vasopressin Vla receptors, by biomimetic catalysts based on metalloporphyrin or Schiff base complexes. Bulletin de la Societé Chimique de France131: 706–712.
25.
HoffmannPLabatGRobertA & MeunierB (1990) Highly selective bromination of tetramesitylporphyrin: an easy access to robust metalloporphyrins, M-Br8TMP and M-Br8TMPS. Tetrahedron Letters31: 1991–1994.
26.
HoffmannPRobertA & MeunierB (1992) Preparation and catalytic activities of the manganese and iron derivatives of Br8TMP and Cl12-TMP, two robust porphyrin ligands obtained by halogenation of tetramesitylporphyrin. Bulletin de la Societé Chimique de France129: 85–97.
27.
JohnstonMI & HothDF (1993) Present status and future prospects for HIV therapies. Science260: 1286–1293.
28.
LabatG & MeunierB (1989) Factors controlling the reactivity of a ligninase model based on the association of potassium monopersulfate to manganese and iron porphyrin complexes. Journal of Organic Chemistry54: 5008–5011.
29.
LabatG & MeunierB (1990) First example of a chloroperoxidasetype chlorination of dimedone using a supported manganese porphyrin catalyst. Journal of the Chemical Society, Chemical Communications1414–1416.
30.
LabatGSerisJL & MeunierB (1990) Oxidative degradation of aromatic pollutants by chemical models of ligninase based on porphyrin complexes. Angewandte Chemie International Edition in English29: 1471–1473.
31.
LangtryHD & Campoli-RichardsDM (1989) Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs37: 408–450.
32.
LindseyJS & WagnerRW (1989) Investigation of the synthesis of ortho-substituted tetraphenylporphyrins. Journal of Organic Chemistry54: 828–836.
33.
MegninFFaustinoPJLyonRCLelkesPI & CohenJS (1987) Studies on the mechanism of selective retention of porphyrins and metailoporphyrins by cancer cells. Biochimica et Biophysica Acta929: 173–181.
34.
MengGGJamesBRSkovKA & KorbelikM (1994) Porphyrin chemistry pertaining to the design of anti-cancer drugs; part 2, the synthesis and in vitro tests of water-soluble porphyrins containing, in the meso positions, the functional groups: 4-methylpyridinium, or 4-sulfonatophenyl, in combination with phenyl, 4-pyridyl, 4-nitrophenyl, or 4-aminophenyl. Canadian Journal of Chemistry72: 2447–2457.
35.
MitsuyaHYarchoanR & BroderS (1990) Molecular targets for AIDS therapy. Science249: 1533–1544.
36.
NeurathARStrickNHaberfieldP & JiangS (1992) Rapid prescreening for antiviral agents against HIV-1 based on their inhibitory activity in site-directed immunoassays. II. Porphyrins reacting with the V3 loop of gp120. Antiviral Chemistry and Chemotherapy3: 55–63.
37.
PattouDLabatGDefianceSSérisJL & MeunierB (1994) Preparation, catalytic activity of supported metalloporphyrin catalysts on polyvinylpyridine polymers and related molecular modelling studies (case of a proximal ligand provided by the polymer itself). Bulletin de la Societé Chimique de France131: 78–88.
38.
PauwelsRBalzariniJBabaMSnoeckRScholsDHerdewijnPDesmyterJ & De ClercqE (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods20: 309–321.
39.
PopovicMSarngadharanMGReadE & GalloRC (1984) Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science224: 497–500.
40.
PratvielGBernadouJ & MeunierB (1995) Carbon-hydrogen bonds of sugar units as targets for chemical nucleases and drugs. Angewandte Chemie International Edition in English34: 746–769.
41.
ReedJ & KinzelV (1991) A conformational switch is associated with receptor affinity in peptides derived from the CD4-binding domain of gp120 from HIV-1. Biochemistry30: 4521–4528.
SarinPS (1988) Molecular pharmacologic approaches to the treatment of AIDS. Annual Reviews of Pharmacology28: 411–428.
44.
SchinaziRFChuCKPeckAMcMillanAMathisRCannonDJeongL-SBeachJWChoiW-BYeolaS & LiottaDC (1992) Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrobial Agents and Chemotherapy36: 672–676.
45.
ScholsDBabaMPauwelsRDesmyterJ & De ClercqE (1989) Specific interaction of aurintricarboxyfic acid with the human immunodeficiency virus/CD4 cell receptor. Proceedings of the National Academy of Sciences, USA86: 3322–3326.
46.
ScholsDPauwelsRDesmyterJ & De ClercqE (1990) Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycolprotein expressed by T-cells persistendy infected with HIV-1. Virology175: 556–561.
47.
ShimizuKSaitoAShimadaJOhmichiMHiragaYInamatsuTShimadaKTanimuraMFujitaYNishikawaTOgumaT & YamamotoS (1993) Carnitine status and safety after administration of S-1108, a new oral cephem, to patients. Antimicrobial Agents and Chemotherapy37: 1043–1049.
48.
St ClairMHMartinJLTudor-WilliamsGBachMCVavroCLKingDMKellamPKempSD & LarderBA (1991) Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science253: 1557–1559.
49.
TeschkeCMKingJ & PreveligePE (1993) Inhibition of viral capsid assembly by 1,1′-Bi (4-anilinonaphtalene-5-sulfonic acid). Biochemistry32: 10658–10665.
50.
TurkH & FordWT (1991) Epoxidation of styrene with aqueous hypochlorite catalyzed by a manganese (III) porphyrin bound to colloidal anion-exchange particles. Journal of Organic Chemistry56: 1253–1260.
51.
VidalMBonnafousMDefianceSLoiseauPBernadouJ & MeunierB (1993) Model systems for oxidative drug metabolism studies: catalytic behavior of water-soluble metailoporphyrins depends on both the intrinsic robustness of the catalyst and the nature of substrates. Drug Metabolism and Disposition21: 360–365.
52.
VolberdingPALagakosSWKochMAPetinelliCMyersMWBoothDKBalfourHHReichmanRCBartlettJAHirschMSMurphyRLHardyWDSoeiroRFischlMABardettJGMeriganTCHyslopNERichmanDDValentineFTCoreyL & the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases (1990) Zidovudine in asymptomatic human immunodeficiency virus infection. New England Journal of Medicine322: 941–949.
53.
WhittingtonR & BrogdenRN (1992) Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs44: 656–683.
54.
YarchoanRMitsuyaH & BroderS (1993) Challenges in the therapy of HIV infection. Trends in Pharmacological Science14: 196–202.
55.
ZippliesMFLeeWA & BruiceTC (1986) Influence of hydrogen ion activity and general acid-base catalysis on the rate of decomposition of hydrogen peroxide by a novel non-aggregating water-soluble iron (III) tetraphenylporphyrin derivative. Journal of the American Chemical Society108: 4433–4445.
